 Inhibrx Inc NASDAQ: INBX announced initial results from Part 3 combination dose escalation of the Phase 1 trial of INBRX-106 combined with Keytruda for solid tumors. The dose of INBRX-106 was escalated in combination with Keytruda in 21 patients with locally advanced or metastatic solid tumors. 